Imatinib Drug Market Size, Industry Trends, Share and Forecast 2019-2025


Posted June 4, 2020 by mansi3210

Imatinib Drug Market Size, Share & Trends Analysis Report, by Drug Form, Gastrointestinal Stromal Tumors (GIST), Skin Tumors and Forecast Period, 2020-2026

 
FDA approval of imatinib drug for the treatment of different types of cancers by the major players propelling the growth of the imatinib drug market. For instance, in July 2019, Lupin Ltd. announced the launch of Imatinib Mesylate tablets, 100mg (base) and 400 mg (base). Lupin alliance partner Natco had received approval from the US FDA earlier. Lupin’s Imatinib Mesylate Tablet, 100 mg (base) and 400 mg (base) is the generic version of Novartis Pharmaceuticals Corp's Gleevec tablets 100mg and 400 mg.

Request a Free Sample of our Imatinib Drug Market: https://www.omrglobal.com/request-sample/imatinib-drug-market

In October 2018, Dr. Reddy’s Laboratories, Ltd. announced the launch of its Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version Gleevec tablets in the United States market for the treatment of different types of cancer. Imatinib Mesylate is a US FDA approved drug for commercial sale in the US which is expected to boost the imatinib market in the country. Imatinib Mesylate tablets are available in two different strengths i.e. 100 mg and 400 mg.
A full Report of Imatinib Drug Market is Available at: https://www.omrglobal.com/industry-reports/imatinib-drug-market
In September 2017, Mylan N.V. announced the US launch of Imatinib Mesylate Tablets in 100 mg and 400 mg generic version. Mylan received final approval from the U.S Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Imatinib Mesylate tablets can be used for multiple indications including Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome (HES) and aggressive systemic mastocytosis (ASM).
Imatinib Drug Market Segmentation
By Drug Form
• Tablet
• Capsule
By Application

• Blood Cancer (Leukemia and Other Blood Cancers)
• Gastrointestinal Stromal Tumors (GIST)
• Skin Tumors (Dermatofibrosarcoma Protuberans)
• Other Tumors (Systemic Mastocytosis)

Imatinib Drug Market – Segment by Region

North America
• US
• Canada
Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

Company Profiles

• Apotex Inc.
• Cipla, Inc.
• Dr. Reddy’s Laboratory, Ltd.
• Glenmark Pharmaceutical, Ltd.
• Lupin, Ltd.
• Mylan N.V.
• Novartis AG
• Sun Pharmaceutical Industries, Ltd.
• Teva Pharmaceutical Industry, Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/imatinib-drug-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Mansi Jain
Phone 07803040404
Business Address Orion Market Research Pvt Ltd
305-308, Commerce House,
Country India
Categories Business , Health , Medical
Tags Pharmaceuticals, , market research , market analysis , market forecast
Last Updated June 4, 2020